On April 12, 2026, Sheikh Khaled bin Mohamed bin Zayed Al Nahyan arrived in Beijing, China, to engage in discussions that underscore the United Arab Emirates’ commitment to advancing healthcare technology. This visit comes at a pivotal time as the UAE’s 3D ultrasound market transitions from a high-end niche to a procedural standard, reflecting the growing clinical demand for volumetric quantification in prenatal cardiology and image-guided interventions.
In recent months, the UAE has positioned itself as a regional reference and training hub for advanced ultrasound applications. The installed base refresh cycle for ultrasound technology is accelerating, driven by software-driven obsolescence, which emphasizes the need for continuous innovation in the medical field.
Significantly, the UAE has introduced an R&D tax credit regime under Cabinet Decision No. 215 of 2025, which was operationalized by Ministerial Decision No. 24 of 2026. This initiative offers a headline rate of 50% on qualifying expenditure, structured in a tiered format: 15% for Tier 1, 35% for Tier 2, and 50% for Tier 3, with qualifying expenditures starting from 1 million AED.
The dual-threshold design of the tax credit has direct implications for transfer pricing compliance, as it requires that the headcount requirement cannot be satisfied through intra-group secondments recharged from other tax group members. This regulatory framework aims to foster a robust environment for research and development in the UAE.
As Sheikh Khaled engages with Chinese counterparts, the discussions are expected to focus on enhancing collaboration in healthcare technology and exploring further investments in R&D initiatives. The UAE’s commitment to innovation is evident, and the R&D tax credit is a testament to its efforts to attract and retain talent in this critical sector.
This sequence of events highlights the UAE’s strategic approach to becoming a leader in healthcare technology, which not only benefits the local economy but also enhances its reputation on the global stage. The advancements in the 3D ultrasound market and the supportive tax environment are crucial for stakeholders involved in healthcare innovation.
As the UAE continues to evolve as a hub for medical advancements, the implications of these developments will resonate throughout the region and beyond, fostering a community focused on health and well-being.
